More Articles

Access! 2019 AAM Annual Meeting Conferences | Posted 30/11/2018

Access! 2019 AAM Annual Meeting 4–6 February 2019 Hyatt Regency New OrleansNew Orleans, LA, USA

International policies for interchangeability, switching and substitution of biosimilars Reports | Posted 23/11/2018

In its report into different international policies on the use of biosimilars, the Canadian Agency for Drugs and Technologies in Health (CADTH) investigated the issue of interchangeability, switchi...

Safety of originator and biosimilar epoetin alfa drugs Biosimilars/Research | Posted 23/11/2018

Researchers from Italy carried out a study to compare the safety profile of biosimilars with respect to the reference product in a nephrology setting. The results confirm the comparable safety prof...

Insulin glargine biosimilars launched in UK and South Korea Biosimilars/News | Posted 23/11/2018

November 2018 has seen the launch of insulin glargine biosimilars in both the UK and South Korea.

FDA strengthens and modernizes inspections for sterile injectable drugs Policies & Legislation | Posted 23/11/2018

On 9 November 2018, the US Food and Drug Administration (FDA) announced that it was taking new steps to modernize its inspections programme with a new way of assessing, recording and reporting the...

AbbVie makes more deals delaying adalimumab biosimilars in US Pharma News | Posted 23/11/2018

Last update: 14 December 2018US-based pharma giant AbbVie has signed yet more deals with biosimilars makers regarding biosimilar versions of its blockbuster arthritis drug Humira (adalimumab).

Tanvex BioPharma submits filgrastim biosimilar to FDA Biosimilars/News | Posted 23/11/2018

Taiwan-based biosimilars developer Tanvex BioPharma (Tanvex) announced on 1 October 2018 that it had submitted its first biosimilar application to the US Food and Drug Administration (FDA). The app...

Positive phase III data for adalimumab biosimilar Cyltezo Biosimilars/Research | Posted 23/11/2018

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) announced on 12 September 2018 positive phase III data for its adalimumab biosimilar, Cyltezo [1]. The results, according t...